| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.085 | 0.03 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.03 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.03 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.086 | 0.04 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.065 | 0.04 |